AOD-9604

Quick Facts

Introduction

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH) — specifically the fragment that research has linked to growth hormone's fat-metabolism effects. The name AOD stands for "Anti-Obesity Drug," reflecting the research goal behind its design: to isolate growth hormone's lipolytic activity while leaving behind the broader growth-promoting and glucose-related effects of the full-length hormone.

The conceptual appeal of AOD-9604 lies in fragment biology. Full-length growth hormone has many actions — it raises IGF-1, influences glucose handling, and promotes tissue growth — and many of these reside in distinct regions of the molecule. Researchers identified that the 177-191 C-terminal segment carries much of the fat-metabolism activity, and AOD-9604 is a stabilized version of that segment studied in isolation.

This profile covers what AOD-9604 is, the structural origin of its fragment design, its proposed lipolytic mechanism, the fat-metabolism research it appears in, and how it compares with growth-hormone-axis and metabolic compounds such as Tesamorelin and Semaglutide. Related entries are catalogued in the peptide database.

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 177-191 at the hormone's C-terminus, with an additional tyrosine residue added at the N-terminus to improve stability. This compact fragment — far smaller than the full 191-residue growth hormone — was designed to retain the lipolytic signal located in this region without reproducing the rest of the hormone's activity.

The central research claim distinguishing AOD-9604 from full-length GH and from GH secretagogues is that it is reported to stimulate fat metabolism without raising IGF-1 and without the effects on blood glucose associated with growth hormone itself. This separation of effects is what made the fragment attractive as a research tool — though, as with all such claims, the supporting evidence is preclinical-heavy and described cautiously below.

Molecular and structural characteristics

Structurally, AOD-9604 reproduces the 177-191 C-terminal loop of human growth hormone, a region that includes a disulfide bond important to its conformation. The added N-terminal tyrosine is a deliberate modification intended to improve the fragment's stability and handling relative to the unmodified natural segment.

Because it is a short fragment rather than the intact hormone, AOD-9604 lacks the regions of growth hormone responsible for engaging the full growth-hormone receptor signaling cascade in the way the complete molecule does — the structural basis for the claim that it separates lipolytic activity from the hormone's other effects.

Mechanism of action

The proposed mechanism of AOD-9604 centers on lipolysis — the breakdown of stored triglycerides in adipose tissue — and on the inhibition of lipogenesis, the formation of new fat. In preclinical models, the C-terminal growth-hormone fragment is associated with stimulating fat breakdown in adipocytes, mirroring one of the well-established actions of full-length growth hormone but in a more targeted fashion.

A distinguishing claim in the research literature is that AOD-9604 reportedly achieves these fat-metabolism effects without binding the growth-hormone receptor in the manner that elevates IGF-1 and without the insulin-antagonizing, glucose-raising effects associated with growth hormone. Some research has explored whether the fragment influences beta-3 adrenergic receptor signaling in adipose tissue as part of its lipolytic action, though the precise receptor-level mechanism remains incompletely defined.

This makes AOD-9604 mechanistically distinct from growth-hormone-axis peptides such as Tesamorelin and CJC-1295, which work by stimulating release of the full growth-hormone molecule and therefore do raise IGF-1. AOD-9604 instead attempts to capture only the fat-metabolism arm of growth-hormone biology.

• Associated with stimulation of lipolysis in adipose tissue.
• Studied for inhibition of lipogenesis (new fat formation).
• Reported to act without elevating IGF-1.
• Investigated for involvement of beta-3 adrenergic signaling in fat cells.

Fat-metabolism research applications

AOD-9604's primary research context is fat metabolism. Preclinical studies in animal models reported associations with reduced body fat and stimulated lipolysis, which formed the basis for its development as a candidate anti-obesity compound. The appeal of the fragment approach was the prospect of fat-loss-relevant activity without the safety considerations attached to full-length growth hormone.

Human clinical research on AOD-9604 for body-weight endpoints has been more limited and less conclusive than the preclinical work, with results that did not consistently replicate the robust fat-loss effects seen in animal models. As a result, the compound is best understood as a research tool whose strongest data come from preclinical settings, rather than as an established fat-loss agent. The broader fat-loss research landscape is catalogued in the peptide database.

Other research directions

Beyond fat metabolism, AOD-9604 has been examined in research exploring joint and cartilage contexts, sometimes in combination with other agents, on the rationale that growth-hormone-derived fragments might influence connective-tissue maintenance. These directions are more exploratory than the fat-metabolism work and rest on a thinner evidence base.

Because AOD-9604 is a growth-hormone fragment, researchers also study it in the broader context of how distinct regions of large hormones can be isolated to separate their multiple effects — a theme relevant across peptide research and one reason the fragment remains of conceptual interest even where its clinical fat-loss data are limited.

Comparison: AOD-9604 vs Tesamorelin vs Semaglutide

AOD-9604 is mechanistically distinct from the GH-axis and incretin compounds it is often discussed alongside. Tesamorelin is a GHRH analogue that raises full-length growth hormone and IGF-1, while Semaglutide is a GLP-1 receptor agonist acting on gut-hormone receptors.

Where Tesamorelin works through the full growth-hormone axis and Semaglutide through appetite, AOD-9604 attempts to isolate growth hormone's direct fat-metabolism effect. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

As a short peptide fragment, AOD-9604 has a relatively short half-life, on the order of minutes to a low number of hours, reflecting rapid clearance typical of small unmodified peptides. The added N-terminal tyrosine improves stability somewhat but does not confer the long duration seen in albumin-binding peptides such as the incretin agonists.

This short duration shapes how the fragment is studied, with research protocols structured around its rapid clearance. As always in peptide research, pharmacokinetic figures are treated as study-specific rather than universal.

Reconstitution and handling considerations

Lyophilized AOD-9604 is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the fragment. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized AOD-9604 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

AOD-9604's evidence base is uneven: its strongest fat-metabolism data come from preclinical animal models, while human research has been more limited and did not consistently reproduce those effects. The mechanistic claim that it stimulates lipolysis without growth-hormone-like effects on IGF-1 and glucose, while central to its rationale, rests on a research base that remains incompletely defined. It is described here strictly for research reference.

• Strongest data are preclinical; human results were less conclusive.
• The IGF-1-sparing mechanistic claim is incompletely defined.
• Short half-life as an unmodified peptide fragment.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.Source
2. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000.Source
3. Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013.